Horizon Therapeutics (HZNP) Tops Q2 EPS by 74c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
August 4, 2021 7:00 AM EDT-- Record Second-Quarter 2021 Net Sales of $832.5 Million Increased 80 Percent; Second-Quarter 2021 GAAP Net Income of $158.1 Million; Adjusted EBITDA of $366.9 Million --
-- Record TEPEZZA® (teprotumumab-trbw) Second-Quarter 2021 Net Sales of $453.3 Million Driven by Strong Demand and Relaunch Execution; Increasing Full-Year 2021 Net Sales Guidance to Greater Than $1.550 Billion and Expect Fourth-Quarter Year-Over-Year Growth of More Than 50 Percent --
-- Record KRYSTEXXA® (pegloticase injection) Second-Quarter 2021 Net Sales of $130.3 Million Increased 73 Percent; KRYSTEXXA Plus Immunomodulation Now at More Than 40 Percent --
-- Increasing Full-Year 2021 Net Sales Guidance to $3.025 Billion to $3.125 Billion,... More
